Authors: M. Lukáš; D. Ďuricová Authors‘ workplace: Klinické a výzkumné centrum pro střevní záněty, Klinické centrum ISCARE a. s. a 1. LF UK v Praze Published in: Gastroent Hepatol 2024; 78(2): 170-172 Category: doi: https://doi.org/10.48095/ccgh2024170
1. Lukáš M. Biologická a inovativní terapie. In: Lukáš M. Pokroky v diagnostice a léčbě idiopatických střevních zánětů. Praha: Galén 2019.
2. D’Amico F, Magro F, Peyrin-Biroulet L et al. Positioning filgotinib in the treatment algorithm of moderate to severe ulcerative colitis. J Crohn’s Colitis 2022; 16 (5): 835–844. doi: 10.1093/ecco-jcc/jjab206.
3. Feagan B, Danese S, Loftus EV et al. Filgotinib as induction and maintenance therapy for ulcerative colitis (SELECTION): a phase 2b/3double – blind, randomized controlled study. Lancet 2021; 397 (10292): 2372–2384. doi: 10.1016/S0140-6736 (21) 00666-8.
4. Schregel I, Ramos GP, Ioannou S et al. Evaluation of tofacitinib in primary sclerosing cholangitis and associated colitis: A multicenter, retrospective study. Clin Gastro Hepatol 2023; 21 (12): 3448–3450. doi: 10.1016/j.cgh.2023.01. 014.
Don‘t have an account? Create new account
Enter the email address that you registered with. We will send you instructions on how to set a new password.
